STOCK TITAN
  1. Home
  2. Sec-filings
  3. BLTE
  4. [Form 4] BELITE BIO, INC Insider Trading Activity

Belite Bio (NASDAQ: BLTE) CSO pre-planned sale of 1,000 ADS disclosed

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Belite Bio Chief Scientific Officer Nathan L. Mata reported open‑market sales of a total of 1,000 American depositary shares on April 21, 2026 at prices within ranges from $163.26 to $167.94. Each ADS represents one ordinary share of the company.

The transactions were executed under a pre‑arranged Rule 10b5-1 trading plan adopted on December 10, 2025. Following these sales, Mata holds 12,602 American depositary shares directly.

Positive

  • None.

Negative

  • None.
Insider MATA NATHAN L.
Role Chief Scientific Officer
Sold 1,000 shs ($166K)
Type Security Shares Price Value
Sale American depositary share 64 $163.4948 $10K
Sale American depositary share 78 $164.6006 $13K
Sale American depositary share 332 $165.4935 $55K
Sale American depositary share 312 $166.4858 $52K
Sale American depositary share 214 $167.3386 $36K
Holdings After Transaction: American depositary share — 12,602 shares (Direct, null)
Footnotes (1)
  1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/10/2025. Represents the weighted average price of shares sold at prices that ranged from $163.26 to $163.88. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $164.11 to $164.93. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $165.09 to $165.98. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $166.07 to $166.98. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $167.01 to $167.94. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
Total ADS sold 1,000 American depositary shares Open-market sales on April 21, 2026
Post-transaction holdings 12,602 American depositary shares Directly held by Nathan L. Mata after sales
Price range of sales $163.26 to $167.94 per ADS Ranges cited in footnotes for April 21, 2026 trades
Single reported trade size 332 ADS at $165.4935 One of five reported open-market sale tranches
Largest reported tranche 332 ADS Maximum shares in a single transaction entry on April 21, 2026
American depositary share financial
"Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer."
An American Depositary Share (ADS) is a U.S.-listed certificate that represents a specified number of shares in a foreign company, held by a custodian bank; it works like a receipt that allows U.S. investors to buy and trade foreign equity on American exchanges without dealing with another country’s markets. Investors care because ADSs make foreign stocks easier to access, improve liquidity and settlement in dollars, and can affect dividend payments, voting rights and regulatory oversight compared with buying the underlying foreign shares directly.
Rule 10b5-1 trading plan regulatory
"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/10/2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"Represents the weighted average price of shares sold at prices that ranged from $163.26 to $163.88."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
MATA NATHAN L.
(Last)(First)(Middle)
7708 MARKER ROAD
(Street)
SAN DIEGO CALIFORNIA 92130
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
BELITE BIO, INC [ BLTE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Scientific Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/21/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
American depositary share(1)04/21/2026S(2)64D$163.4948(3)12,602D
American depositary share(1)04/21/2026S(2)78D$164.6006(4)12,524D
American depositary share(1)04/21/2026S(2)332D$165.4935(5)12,192D
American depositary share(1)04/21/2026S(2)312D$166.4858(6)11,880D
American depositary share(1)04/21/2026S(2)214D$167.3386(7)11,666D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer.
2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/10/2025.
3. Represents the weighted average price of shares sold at prices that ranged from $163.26 to $163.88. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
4. Represents the weighted average price of shares sold at prices that ranged from $164.11 to $164.93. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
5. Represents the weighted average price of shares sold at prices that ranged from $165.09 to $165.98. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
6. Represents the weighted average price of shares sold at prices that ranged from $166.07 to $166.98. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
7. Represents the weighted average price of shares sold at prices that ranged from $167.01 to $167.94. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
/s/ Nathan L. Mata04/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Belite Bio (BLTE) disclose in this Form 4?

Belite Bio disclosed that Chief Scientific Officer Nathan L. Mata sold 1,000 American depositary shares on April 21, 2026. The sales were executed in multiple open‑market trades at prices ranging from $163.26 to $167.94 under a pre‑arranged Rule 10b5-1 plan.

Who is the insider involved in the latest Belite Bio (BLTE) Form 4 filing?

The insider is Nathan L. Mata, Chief Scientific Officer of Belite Bio. He reported several open‑market sales totaling 1,000 American depositary shares on April 21, 2026, and now holds 12,602 ADS directly according to the filing.

How many Belite Bio (BLTE) shares did the insider sell and at what prices?

The insider sold 1,000 American depositary shares in total. The trades occurred at weighted average prices around $163–$167 per ADS, with specific ranges between $163.26 and $167.94 as detailed in the Form 4 footnotes.

Does the Belite Bio (BLTE) Form 4 indicate use of a Rule 10b5-1 trading plan?

Yes. The filing states the sales were made under a Rule 10b5-1 trading plan. The plan was adopted by Nathan L. Mata on December 10, 2025, indicating the April 21, 2026 transactions were pre‑scheduled rather than discretionary trades.

What is the insider’s Belite Bio (BLTE) position after the reported sales?

After the reported transactions, Nathan L. Mata directly holds 12,602 American depositary shares. Each ADS represents one ordinary share of Belite Bio, providing a clear view of his remaining direct equity stake following the 1,000-share sale.